CRMD - CorMedix - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRMD is currently covered by 4 analysts with an average price target of $18.8. This is a potential upside of $7.13 (61.1%) from yesterday's end of day stock price of $11.67.

CorMedix's activity chart (see below) currently has 34 price targets and 51 ratings on display. The stock rating distribution of CRMD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.74% with an average time for these price targets to be met of 431.13 days.

Highest price target for CRMD is $20, Lowest price target is $12, average price target is $16.

Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 30-Jun-2025. First documented stock forecast 12-Dec-2018.

Currently out of the existing stock ratings of CRMD, 27 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

1 months 2 days ago
(30-Jun-2025)

7/7 (100%)

$-1.56 (-9.42%)

92

Buy

$20

$8.51 (74.06%)

$15

1 months 8 days ago
(24-Jun-2025)

14/17 (82.35%)

$4.28 (27.23%)

353

Buy

$12

$0.51 (4.44%)

$12

4 months 6 days ago
(26-Mar-2025)

5/5 (100%)

$4.84 (67.60%)

171

Buy

1 years 8 months 17 days ago
(15-Nov-2023)

0/1 (0%)

$8.28 (70.65%)

Buy

$19

$7.51 (65.36%)

$16

2 years 2 months 13 days ago
(19-May-2023)

2/9 (22.22%)

$13.9 (272.55%)

925

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRMD (CorMedix) average time for price targets to be met?

On average it took 431.13 days on average for the stock forecasts to be realized with a an average price target met ratio 54.74

Which analyst has the current highest performing score on CRMD (CorMedix) with a proven track record?

JASON BUTLER

Which analyst has the current lower performing score on CRMD (CorMedix) with a proven track record?

RAGHURAM SELVARAJU

Which analyst has the most public recommendations on CRMD (CorMedix)?

Jason Butler works at JMP and has 6 price targets and 7 ratings on CRMD

Which analyst is the currently most bullish on CRMD (CorMedix)?

Andrew D'silva with highest potential upside - $20.02

Which analyst is the currently most reserved on CRMD (CorMedix)?

James Lee with lowest potential downside - -$0

CorMedix in the News

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?